Novel and selective inhibitors of SRC family kinases

submit enquiry
cancer cells
cancer cells

University: University of Edinburgh

Sector(s): Healthcare & Pharmaceuticals, Life Sciences

About Opportunity:

SRC is a non-receptor tyrosine kinase, which is overexpressed and/or over-activated in many types of cancer. SRC has been shown to have a crucial role in many aspects of tumour growth and development, including proliferation, migration, invasion, angiogenesis, metastasis and resistance to chemotherapy. Increased expression and activity of SRC correlate with advanced malignancy and poor clinical prognosis. All current SRC inhibitors display potent activity against Abl1, which results in undesired side effects (such as cardiotoxicity) and lower anti-cancer activity in certain tumour types.

Novel compounds displaying high potency and selectivity toward SRC family kinases have been developed by combining ligand-based design and phenotypic screening in an iterative manner.


The preclinical candidate eCF506 inhibits SRC kinase at subnanomolar levels with very high selectivity over ABL (>1000-fold). The compound displays excellent drug-like physiochemical properties, and is orally bioavailable with excellent efficacy in cells (EC50 below 10 nM) and in vivo pharmacokinetic profile. Inhibition of SRC phosphorylation and downstream signaling (FAK, paxillin) following oral, iv and IP administration has been demonstrated in breast and colorectal cancer xenograft models.

Proof of concept experiments have been conducted in vitro and in vivo, in zebrafish and xenograft models of breast and colorectal cancer.

Key Benefits:

  • High anti-proliferative and anti-invasive activity in various cancer cell lines
  • Improved Safety: no ABL inhibition liability, which is associated with cardiotoxicity
  • Good oral bioavailability, half-life, stability


  • Oncology: combination therapies in advanced cancer disease
  • Diabetic eye disease
  • Neurodegenerative diseases

IP Status:

Lead series chemistry is protected by a patent application

(WO 2016/185160 A1)


Please enter your name.

Please enter the name of the company you work for.

Is your company an SME?

Please select the country you are in.

Please select what part of the UK you are in.

Please select from the following options.

Please enter your email address.

To help us process your enquiry faster please enter some details about the information you are interested in.

Words remaining:

Related Opportunities

  • Telomerase Promoter - Cancer Therapies

    The University of Glasgow has developed a (Ad-hTR-NTR) which has been extensively tested on Ovarian cancer cells.

    Expires: Created:
  • SNP-based assay for analysis of MRSA

    This assay is a rapid and reproducible approach for epidemiological analysis of methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. The assay identifies different strains on EMRSA-15, which is a major cause of hospital acquired MRSA infections in the UK and in other parts of the wo...

    Expires: Created:
  • Catanostics - Non-Invasive Early Stage Cataract Diagnosis & Severity Quantification tool

    Catanostics (Cataract Diagnostics) offers an alternative to the slit lamp currently used for cataract diagnosis before referring a patient for cataract surgery. Our non-invasive fluorescence scan offers "better diagnosis" through non-subjective analysis of data on cataract symptoms & severity lea...

    Expires: Created:
  • Transforming Pharmaceutical Crystal Forms

    The innovation provides a gas-induced method for phase-transforming organic solids, such as pharmaceutical crystals. The inventive method subjects the polymorphs of pharmaceutical agents to various pressures of gases (such as CO2, N2O, and CH4) to induce phase transform with ease.

    Expires: Created:
  • Sperm Motility Enhancers for Assisted Reproductive Technology

    Sperm Motility Enhancers: A Novel Strategy for Assisted Reproductive Technology (ART) based on the direct relationship between human fertility and sperm motility,the University of Dundee has successfully identified FDA-approved compounds with robust and effective stimulation on patient sperm motilit...

    Expires: Created:

Alerts Signup

Sign up to our technology alerts and be the first to hear about any new technology opportunities from Scotland's universities

Register Now for University Alerts

Search Filter

Share this page

Use the buttons below to share these technology opportunities on your favourite social networking site. You can also share them from inside the individual opportunity.